GoodRx (GDRX) Shares Down 28% on Q4 Miss, Weak Outlook

GoodRx Holdings, Inc. (NASDAQ: GDRX) shares were trading around 28% lower after-hours following the company’s disappointing Q4 results. Quarterly EPS came in at $0.09, missing the consensus estimate of $0.10.

Revenue was $213.3 million, compared to the consensus estimate of $217.53 million. Prescription Transactions revenue increased 21% year-over-year to $158.8 million, driven by a 14% increase in monthly active consumers (MAC) and an ongoing increase in revenue per MAC. Subscription revenue was $17.4 million, up 79% year-over-year, driven by a 51% increase in the number of subscription plans and a favorable change in the subscription plan mix.

The company’s Board of Directors authorized the repurchase of up to $250 million of its Class A common stock.

The company expects Q1/22 revenue of around $200 million, compared to the consensus estimate of $227.92 million. For the full 2022-year, the company anticipates around 23% year-over-year growth.

You May Also Be Interested In

• Regenxbio shares jump after FDA agrees to reverse drug rejection
• Alphabet (GOOGL) falls over 5%
• Trump on Iran: Strait of Hormuz is totally open